Trial Updates

Randomized trial of FUS subthalamotomy for PD 4:10
Randomized trial of FUS subthalamotomy for PD
José Obeso et al. • 22 Apr 2021
REGAIN study and extension trial of eculizumab in myasthenia gravis 1:34
REGAIN study and extension trial of eculizumab in myasthenia gravis
James F. Howard Jr. • 7 Apr 2021
Mindfulness meditation vs. headache education for migraine treatment 5:21
Mindfulness meditation vs. headache education for migraine treatment
Rebecca E. Wells • 20 Apr 2021
Concomitant immunosuppressive therapy in gMG patients on the REGAIN extension study 1:02
Concomitant immunosuppressive therapy in gMG patients on the REGAIN extension study
James F. Howard Jr. • 7 Apr 2021
Open-label extension study of lecanemab in early Alzheimer’s disease 4:57
Open-label extension study of lecanemab in early Alzheimer’s disease
Chad Swanson • 26 Apr 2021
The impact of COVID-19 in the UK MS Register COVID-19 prospective cohort study 5:36
The impact of COVID-19 in the UK MS Register COVID-19 prospective cohort study
Afagh Garjani • 26 Apr 2021
INTREPID trial: device features and study design 5:06
INTREPID trial: device features and study design
Jerrold Vitek • 16 Apr 2021
Updates on the INTREPID trial: 4-year follow-up 5:11
Updates on the INTREPID trial: 4-year follow-up
Jerrold Vitek • 16 Apr 2021
ADAPT analysis: efgartigimod for generalized myasthenia gravis 4:59
ADAPT analysis: efgartigimod for generalized myasthenia gravis
James F. Howard Jr • 7 Apr 2021
STOP 301: non-oral INP104 for the acute treatment of migraine 1:34
STOP 301: non-oral INP104 for the acute treatment of migraine
Jessica Ailani • 18 Apr 2021
Atogepant meets all endpoints in the Phase III ADVANCE trial for episodic migraine prevention 3:02
Atogepant meets all endpoints in the Phase III ADVANCE trial for episodic migraine prevention
Jessica Ailani • 18 Apr 2021
Ubrogepant safety by age, gender and race 1:06
Ubrogepant safety by age, gender and race
Jessica Ailani • 18 Apr 2021
Rimegepant to treat acute migraine in patients with cardiovascular risk factors 2:36
Rimegepant to treat acute migraine in patients with cardiovascular risk factors
Susan Hutchinson • 21 Apr 2021
Neurological complications of COVID-19: first analysis of the GCS-NeuroCOVID study 11:01
Neurological complications of COVID-19: first analysis of the GCS-NeuroCOVID study
Sherry Chou • 20 Apr 2021
Upcoming treatments for migraine: zavegepant, rimegepant and atogepant 3:02
Upcoming treatments for migraine: zavegepant, rimegepant and atogepant
Jessica Ailani • 18 Apr 2021
Sustained benefits using spinal cord stimulation for the treatment of painful diabetic neuropathy 4:12
Sustained benefits using spinal cord stimulation for the treatment of painful diabetic neuropathy
Erika Petersen • 9 Apr 2021
The content of VJNeurology is intended for healthcare professionals